Lung Surgery After Age 80: A Risk or an Opportunity?
In this article
A multicenter analysis demonstrating that chronological age is not a barrier in modern oncology: lung cancer surgery in patients over 80.
Study Methodology and Patient Profile
This study focused not only on numerical data but also on patients' postoperative quality of life. Here is the study's technical framework:
Patient Selection Criteria
Patients aged 80 and older (octogenarians) included in the study were assessed according to the following criteria:
- Staging: Stage I-IIIA non-small cell lung cancer (NSCLC).
- Functional Status: ECOG performance status 0 or 1.
- Respiratory Reserve: FEV1 above 60% of the predicted value.
- Cardiac Status: No history of unstable angina or heart failure within the past 6 months.
Key Findings: Is Older Age a Barrier?
The rate of major complications (Grade 3+) was 12.8% in the group over 80 and 10.2% in the control group under 65. This difference was not statistically significant.
By postoperative month 3, 88% of patients had fully resumed their daily activities, including walking without assistance and personal care.
30-Day Mortality Rates (Safety)
| Parameter | 80+ Age Group | Younger Group | P Value |
|---|---|---|---|
| Median Operating Time | 145 Minutes | 138 Minutes | 0.42 (Not Significant) |
| Need for Intensive Care | %18.2 | %14.5 | 0.15 (Not Significant) |
| 5-Year Survival (Stage I) | %68 | %74 | 0.08 (Similar) |
DROZDOGAN Academy Commentary: What Do the Data Tell Us?
The most striking finding of this study is that, in patients over 80, “oncological outcomes” are almost the same as in younger patients. In other words, older patients who undergo surgery not only come through the operation successfully but also achieve similar success to younger patients in fighting cancer.
The golden rule here is “Appropriate Selection”. If the patient's lung function is adequate and minimally invasive surgery (VATS/robotic surgery) is available, age alone should not be a reason for exclusion. Medicine should be guided by biological resilience, not chronological age.
References
- The Lancet Regional Health - Europe, Vol 42, 100912, April 2026
- International Association for the Study of Lung Cancer (IASLC) 2026 Guidelines.
- “Geriatric Assessment in Surgical Oncology.” Annals of Surgical Oncology. 2026.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.